Johnson & Johnson (NYSE:JNJ) Shares Sold by BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp reduced its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 13.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 401,576 shares of the company's stock after selling 59,993 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp's holdings in Johnson & Johnson were worth $65,079,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of JNJ. Encompass More Asset Management purchased a new position in Johnson & Johnson during the third quarter worth approximately $398,000. Acropolis Investment Management LLC increased its stake in shares of Johnson & Johnson by 1.8% in the 3rd quarter. Acropolis Investment Management LLC now owns 22,055 shares of the company's stock worth $3,574,000 after acquiring an additional 384 shares during the last quarter. Kolinsky Wealth Management LLC raised its holdings in shares of Johnson & Johnson by 4.0% during the 3rd quarter. Kolinsky Wealth Management LLC now owns 2,186 shares of the company's stock worth $354,000 after acquiring an additional 84 shares during the period. Ironwood Investment Counsel LLC boosted its position in shares of Johnson & Johnson by 0.6% during the 3rd quarter. Ironwood Investment Counsel LLC now owns 62,061 shares of the company's stock valued at $10,058,000 after acquiring an additional 393 shares during the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec grew its holdings in shares of Johnson & Johnson by 29.6% in the third quarter. Caisse DE Depot ET Placement DU Quebec now owns 3,289,172 shares of the company's stock valued at $533,043,000 after purchasing an additional 750,315 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. Royal Bank of Canada raised their target price on Johnson & Johnson from $178.00 to $181.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 16th. Citigroup boosted their price objective on shares of Johnson & Johnson from $180.00 to $185.00 and gave the company a "buy" rating in a report on Wednesday, October 16th. Morgan Stanley boosted their price target on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an "equal weight" rating in a research note on Wednesday, October 16th. Wolfe Research initiated coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They issued an "outperform" rating and a $190.00 target price for the company. Finally, Guggenheim raised their price target on Johnson & Johnson from $156.00 to $162.00 and gave the stock a "neutral" rating in a research report on Wednesday, November 6th. Seven equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $175.94.

Johnson & Johnson Stock Down 0.2 %

Johnson & Johnson stock opened at $155.08 on Friday. The stock has a 50-day simple moving average of $159.15 and a 200-day simple moving average of $156.40. The company has a market capitalization of $373.37 billion, a P/E ratio of 22.44, a PEG ratio of 2.76 and a beta of 0.53. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. During the same quarter in the prior year, the firm earned $2.66 EPS. Johnson & Johnson's revenue for the quarter was up 5.2% on a year-over-year basis. Equities research analysts expect that Johnson & Johnson will post 9.93 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be given a $1.24 dividend. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a yield of 3.20%. Johnson & Johnson's dividend payout ratio (DPR) is 71.78%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.